Product Name:5-Bromo-2-chloro-3-nitropyridine

IUPAC Name:5-bromo-2-chloro-3-nitropyridine

CAS:67443-38-3
Molecular Formula:C5H2BrClN2O2
Purity:98%
Catalog Number:CM102635
Molecular Weight:237.44

Packing Unit Available Stock Price($) Quantity
CM102635-250g in stock ŮŤƈ
CM102635-500g in stock ŤŤIJ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:67443-38-3
Molecular Formula:C5H2BrClN2O2
Melting Point:-
Smiles Code:O=[N+](C1=CC(Br)=CN=C1Cl)[O-]
Density:
Catalog Number:CM102635
Molecular Weight:237.44
Boiling Point:285.4°C at 760 mmHg
MDL No:MFCD00222270
Storage:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

XRD-0394
XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.

Related Products